MarketBeat | Real-Time Financial News and Analysis

Open Main Menu Open Sidebar

Antares Pharma Company Profile (NASDAQ:ATRS)

Consensus Ratings for Antares Pharma (NASDAQ:ATRS) (?)
Ratings Breakdown: 2 Buy Rating(s)
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $3.50 (267.18% upside)

Analysts' Ratings History for Antares Pharma (NASDAQ:ATRS)
Show:
DateFirmActionRatingPrice TargetActions
5/10/2016Jefferies GroupReiterated RatingBuy$3.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
9/25/2015OppenheimerReiterated RatingBuy$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
5/18/2015Piper JaffrayInitiated CoverageOverweight$3.50View Rating Details  Tweet This Rating  Share This Rating on StockTwits
10/22/2014JMP SecuritiesInitiated CoverageOutperform$4.00View Rating Details  Tweet This Rating  Share This Rating on StockTwits
(Data available from 6/25/2014 forward)
Earnings History for Antares Pharma (NASDAQ:ATRS)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallActions
8/8/2016        
5/9/2016Q1($0.03)($0.05)$11.10 million$12.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/8/2016Q415($0.03)($0.04)$12.53 million$11.80 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/5/2015Q3 15($0.03)($0.04)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/10/2015Q215($0.03)($0.01)$10.93 million$14.40 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/11/2015Q115($0.04)($0.05)$9.22 million$8.30 millionViewListenView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/12/2015Q414($0.05)($0.08)$8.50 million$8.40 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2014($0.07)($0.05)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2014Q214($0.07)($0.07)$6.43 million$6.30 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/9/2014Q114($0.05)($0.07)$6.17 million$5.20 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2014Q413($0.05)($0.04)$6.20 million$4.70 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/6/2013Q313($0.04)($0.05)$5.86 million$5.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/7/2013Q2 2013($0.03)($0.04)$5.82 million$5.84 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
5/8/2013Q1 2013($0.03)($0.03)$5.12 million$4.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
3/13/2013Q4 2012($0.03)($0.04)$5.36 million$5.50 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
11/7/2012Q312($0.03)($0.03)$5.62 million$5.68 millionViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
8/8/2012($0.03)($0.03)ViewN/AView Earnings Details  Tweet This Announcement  Share This Announcement on StockTwits
(Data available from 1/1/2011 forward)
Earnings Estimates for Antares Pharma (NASDAQ:ATRS)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161($0.04)($0.04)($0.04)
Q2 20161($0.04)($0.04)($0.04)
Q3 20162($0.03)$0.02($0.01)
Q4 20161($0.04)($0.04)($0.04)
(Data provided by Zacks Investment Research)
Dividend History for Antares Pharma (NASDAQ:ATRS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trading History for Antares Pharma (NASDAQ:ATRS)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionActions
3/21/2016Peter J GrahamSVPBuy20,000$0.77$15,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016James E FickenscherCFOBuy135,000$0.72$97,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Leonard S JacobDirectorBuy50,000$0.72$36,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/18/2016Robert F AppleCEOBuy60,000$0.72$43,200.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/30/2015James E FlynnMajor ShareholderSell249,998$1.69$422,496.62View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/29/2015James E FlynnMajor ShareholderSell225,048$1.82$409,587.36View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/28/2015James E FlynnMajor ShareholderSell1,353,483$1.81$2,449,804.23View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/24/2015Robert P Roche JrDirectorBuy5,000$1.77$8,850.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2015Robert P Roche JrDirectorBuy5,000$1.94$9,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/20/2015James E FlynnInsiderSell231,793$2.17$502,990.81View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/8/2015James E FlynnMajor ShareholderSell444,341$2.05$910,899.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/7/2015James E FlynnMajor ShareholderSell198,651$2.09$415,180.59View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/6/2015James E FlynnMajor ShareholderSell191,513$2.12$406,007.56View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2015James E FlynnInsiderSell713,222$2.09$1,490,633.98View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/30/2015James E FlynnMajor ShareholderSell608,691$2.08$1,266,077.28View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/29/2015James E FlynnMajor ShareholderSell60,695$2.18$132,315.10View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/26/2015James E FlynnInsiderSell756,852$2.27$1,718,054.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/23/2015James E FlynnInsiderSell499,895$2.39$1,194,749.05View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/18/2015James E FlynnInsiderSell478,366$2.44$1,167,213.04View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/15/2015James E FlynnInsiderSell748,030$2.44$1,825,193.20View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
3/23/2015Leonard S JacobDirectorSell23,500$2.68$62,980.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/10/2014Eamonn P HobbsCEOBuy9,000$2.20$19,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/13/2014Robert P Roche JrDirectorBuy5,000$1.96$9,800.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/11/2014Marvin SamsonDirectorBuy25,000$2.00$50,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
12/9/2013Paul WottonCEOSell64,100$4.00$256,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
10/14/2013Robert AppleCFOSell22,000$5.05$111,100.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Anton GuethDirectorSell25,000$4.42$110,500.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
9/3/2013Paul WottonCEOSell35,000$4.41$154,350.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Anton GuethDirectorSell25,000$4.41$110,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
8/1/2013Paul K WottonCEOSell35,000$4.42$154,700.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Anton GuethDirectorSell25,000$4.15$103,750.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
7/1/2013Paul K WottonCEOSell35,000$4.14$144,900.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/25/2013Eamonn P HobbsDirectorSell23,500$4.19$98,465.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/4/2013Robert F AppleCFOSell115,000$4.02$462,300.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Anton GuethDirectorSell25,000$4.01$100,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Kaushik J DaveEVPSell48,000$4.01$192,480.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
6/3/2013Paul K WottonCEOSell125,000$4.01$501,250.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/31/2013Thomas J GarrityDirectorSell13,000$4.08$53,040.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
5/17/2013Leonard S JacobDirectorSell17,000$4.00$68,000.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
11/16/2012Leonard S JacobDirectorBuy10,000$3.44$34,400.00View SEC Filing  Tweet This Trade  Share This Trade on StockTwits
(Data available from 1/1/2013 forward)
Latest Headlines for Antares Pharma (NASDAQ:ATRS)
DateHeadline
06/24/16 07:44 AMCovering the Bases on Antares Pharma, Inc. (NASDAQ:ATRS): Where is the Stock Going? - Press Telegraph
06/23/16 10:05 PMAntares Pharma (ATRS) Announces Teva (TEVA) Settles Patent Litigation with AstraZeneca (AZN)
06/23/16 04:10 PMAntares Pharma Inc. (NasdaqCM:ATRS) Stock Momentum at Critical Inflection Point - CML News
06/23/16 04:10 PMAntares Pharma (ATRS) Announces Teva (TEVA) Settles Patent Litigation with AstraZeneca (AZN) - StreetInsider.com
06/23/16 09:56 AM10:56 am Antares Pharma announces that Teva Pharmacueticals (TEVA) has settled patent litigation with AstraZeneca (AZN) & Amylin Pharma regarding Byetta -
06/23/16 09:55 AMAntares Pharma Announces Settlement of Patent Litigation for Key Alliance Business Product - [GlobeNewswire] - EWING, N.J., June 23, 2016-- Antares Pharma, Inc. today announced that Teva Pharmaceuticals USA, Inc. has settled the patent litigation with AstraZeneca Pharmaceuticals LP, AstraZeneca AB and Amylin Pharmaceuticals, ...
06/22/16 07:26 AMOverview of Analyst's Recommendations: EXACT Sciences Corporation (NASDAQ:EXAS) , Antares Pharma, Inc ... - Street Updates
06/20/16 01:03 PMETF’s with exposure to Antares Pharma, Inc. : June 20, 2016 -
06/19/16 02:35 PMThis Weeks Broker Views For Antares Pharma, Inc. (ATRS) - Fiscal Standard
06/19/16 07:20 AMWill Antares Pharma, Inc. (NASDAQ:ATRS) Surprise This Quarter? - Investor Newswire
06/17/16 02:37 PMNoteworthy Price Swings: Antares Pharma, Inc. (NASDAQ:ATRS) , ProNAi Therapeutics, Inc. (NASDAQ:DNAI) - Street Updates
06/16/16 08:37 AMANTARES PHARMA, INC. Files SEC form 8-K, Other Events -
06/16/16 07:00 AMNew Broker Ratings For Antares Pharma, Inc. (ATRS) - FTSE News
06/15/16 07:25 AMRecently Issued Stock Ratings For Antares Pharma, Inc. (ATRS) - Fiscal Standard
06/08/16 09:00 PMAntares Pharma Inc. (ATRS) Drops 5.98% on June 07 - Equities.com
06/08/16 07:32 AMANTARES PHARMA, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits -
06/07/16 08:14 PMANTARES PHARMA INC. (NASDAQ:ATRS) Financial Condition Compared to S&P 500 - CML News
06/07/16 03:38 PMANTARES PHARMA, INC. Files SEC form 8-K, Submission of Matters to a Vote of Security Holders -
06/07/16 10:51 AMPrice Fluctuations to Observe: Incyte Corporation (NASDAQ:INCY) , Antares Pharma, Inc. (NASDAQ:ATRS) - Street Updates
06/06/16 02:29 PMStock's Earnings Activity: Take-Two Interactive Software Inc. (NASDAQ:TTWO), Antares Pharma Inc. (NASDAQ:ATRS) - Beacon Chronicle
06/06/16 11:34 AMRecent Trading Updates: Antares Pharma, Inc. (NASDAQ:ATRS) , Becton, Dickinson and Company (NYSE:BDX) - Street Updates
06/03/16 02:10 PMETF’s with exposure to Antares Pharma, Inc. : June 3, 2016 -
06/03/16 11:10 AMShare Rating Focus on Antares Pharma, Inc. (NASDAQ:ATRS) - HNN
06/03/16 11:10 AMAntares Pharma Inc. (ATRS) is Trading Higher on Unusual Volume for June 01 - Equities.com
06/02/16 08:41 PMMix Momentum Detain Active Stocks- Antares Pharma (NASDAQ:ATRS), Incyte (NASDAQ:INCY), Allergan (NYSE:AGN) - Seneca Globe - Seneca GlobeMix Momentum Detain Active Stocks- Antares Pharma (NASDAQ:ATRS), Incyte (NASDAQ:INCY), Allergan (NYSE:AGN)Seneca GlobeAntares Pharma Inc. (NASDAQ:ATRS) rises up 13.40% to close at $1.10 as Antares Pharma, Inc. (ATRS) reported that last patient has completed treatment in a dose-blinded, multiple-dose, concentration controlled 26-week safety and pharmacokinetic phase ...and more »
06/02/16 11:21 AMTarget Price and Stock Performance Rundown for Antares Pharma, Inc. (NASDAQ:ATRS) - HNN - Target Price and Stock Performance Rundown for Antares Pharma, Inc. (NASDAQ:ATRS)HNNKeeping an eye on share activity using multiple views may be helpful when tracking stock performance. Equity investors have the ability to track short or long term share performance. During the latest trading session, Antares Pharma, Inc. (NASDAQ:ATRS) ...and more »
06/02/16 11:21 AMInsiders Are Gradually Buying Antares Pharma Inc. (NASDAQ:ATRS) - HNN - Insiders Are Gradually Buying Antares Pharma Inc. (NASDAQ:ATRS)HNNAccording to the latest SEC filings, insiders at Antares Pharma Inc. (NASDAQ:ATRS) have increased their position in the stock by 3.59% over the past 6 months. Insiders now own 7.00% of total outstanding shares. There are both legal and illegal types of ...and more »
06/01/16 08:47 PMAntares Pharma Inc. (ATRS) Jumps 13.4% on June 01 - Equities.com - Antares Pharma Inc. (ATRS) Jumps 13.4% on June 01Equities.comAntares Pharma Inc. (ATRS) was among the biggest gainers on the Russell 2000 for Wednesday June 01 as the stock popped 13.4% to $1.10, representing a gain of $0.13 per share. Some 1.23 million shares traded hands on 2,514 trades, compared with an ...and more »
06/01/16 08:00 AMAntares Pharma to Present at the Jefferies 2016 Healthcare Conference - [GlobeNewswire] - EWING, N.J., June 01, 2016-- Antares Pharma, Inc. today announced that Robert F. Apple, President and Chief Executive Officer, will present at the Jefferies 2016 Healthcare Conference on Wednesday, June ...
06/01/16 07:33 AMAntares Pharma Announces Update to Quickshot Testosterone Program - [at noodls] - e4b4b4e3-5619-457e-b7d0-b4e9a1af8187.pdf antares pharma ANTARES PHARMA ANNOUNCES UPDATE TO QUICKSHOT TESTOSTERONE CLINICAL PROGRAM LAST PATIENT COMPLETES TREATMENT IN QUICKSHOT SUPPLEMENTAL SAFETY STUDY ...
06/01/16 06:00 AMAntares Pharma Announces Update to QuickShot Testosterone Clinical Program - [GlobeNewswire] - EWING, N.J., June 01, 2016-- Antares Pharma, Inc. today announced that the last patient has completed treatment in a dose-blinded, multiple-dose, concentration controlled 26- week safety and pharmacokinetic ...
05/31/16 08:19 PMAntares Pharma Inc. (ATRS) Jumps 5.64% on May 31 - Equities.com - Antares Pharma Inc. (ATRS) Jumps 5.64% on May 31Equities.comAntares Pharma Inc. (ATRS) was among the biggest gainers on the Russell 2000 for Tuesday May 31 as the stock popped 5.64% to $0.97, representing a gain of $0.0518 per share. Some 515,658 shares traded hands on 1,594 trades, compared with an ...and more »
05/30/16 09:23 PMAntares Pharma, Inc. (NASDAQ:ATRS) Posts Quarterly EPS Of $-0.0494 From Continuing Operations - Stocks Daily - Antares Pharma, Inc. (NASDAQ:ATRS) Posts Quarterly EPS Of $-0.0494 From Continuing OperationsStocks DailyFor the year ended 2016-03-31 Antares Pharma, Inc. (NASDAQ:ATRS) basic consolidated EPS came $-0.1409. However, for the quarter ended 2016-03-31, it was $-0.1409. EPS is a fraction of a firm's profits that is to be paid to each outstanding share.
05/30/16 09:56 AMPerformance at a Glance on Antares Pharma Inc. (NASDAQ:ATRS) - HNN - Performance at a Glance on Antares Pharma Inc. (NASDAQ:ATRS)HNNWhen speculating how a given stock will perform in the future, it is important to look at how it has performed in the past. Today we will examine how Antares Pharma Inc. (NASDAQ:ATRS)'s stock has performed at various points in its past. Currently, the ...and more »
05/27/16 09:47 AMStock Rating Review for Antares Pharma, Inc. (NASDAQ:ATRS) - Wall Street Hints and News - Stock Rating Review for Antares Pharma, Inc. (NASDAQ:ATRS)Wall Street Hints and NewsCovering equity analysts presently have a consensus stock rating of 1 on shares of Antares Pharma, Inc. (NASDAQ:ATRS). Covering analysts will often provide Sell, Hold, or Buy recommendations based on their advanced research. This consensus rating is ...and more »
05/25/16 11:35 PMTarget Check and Stock Performance Recap Antares Pharma, Inc. (NASDAQ:ATRS) - Wall Street Hints and News - Target Check and Stock Performance Recap Antares Pharma, Inc. (NASDAQ:ATRS)Wall Street Hints and NewsTracking stock performance from various views may help with share evaluation. Some investors might be more focused on short-term share action while others may prefer to view long-term performance. In recent session activity, Antares Pharma, Inc.and more »
05/25/16 11:35 PMInsiders Are Gradually Buying Antares Pharma Inc. (NASDAQ:ATRS) - Wall Street Hints and News - Insiders Are Gradually Buying Antares Pharma Inc. (NASDAQ:ATRS)Wall Street Hints and NewsAccording to the latest SEC filings, insiders at Antares Pharma Inc. (NASDAQ:ATRS) have increased their position in the stock by 3.68% over the past 6 months. Insiders now own 7.00% of total outstanding shares. There are both legal and illegal types of ...and more »
05/25/16 11:35 PMAntares Pharma Inc. (ATRS) Jumps 9.43% on May 25 - Equities.com - Antares Pharma Inc. (ATRS) Jumps 9.43% on May 25Equities.comAntares Pharma Inc. (ATRS) was among the biggest gainers on the Russell 2000 for Wednesday May 25 as the stock popped 9.43% to $0.95, representing a gain of $0.0817 per share. Some 853,745 shares traded hands on 1,913 trades, compared with an ...and more »
05/22/16 11:08 AMNext Weeks Broker Price Targets For Antares Pharma, Inc. (ATRS) - Share Trading News - Next Weeks Broker Price Targets For Antares Pharma, Inc. (ATRS)Share Trading NewsAntares Pharma, Inc. has a 50 day moving average of 0.92 and a 200 day moving average of 1.06. The stock's market capitalization is 133.56M, it has a 52-week low of 0.67 and a 52-week high of 2.60. The share price of the company (ATRS) was up +2.63%, ...Antares Pharma, Inc. (NASDAQ:ATRS) Comprehensive Income At $-0.6918Investor NewswireIs it Time to Cash in Profits on Antares Pharma Inc. (NASDAQ:ATRS)Franklin Independentall 3 news articles »
05/20/16 10:13 AMAnalyst Rating Check on Antares Pharma, Inc. (NASDAQ:ATRS) - Wall Street Hints and News - Analyst Rating Check on Antares Pharma, Inc. (NASDAQ:ATRS)Wall Street Hints and NewsCurrently, sell-side analysts have provided a consensus stock rating of 1 on shares of Antares Pharma, Inc. (NASDAQ:ATRS). Analysts that cover the company will usually offer Buy, Sell, or Hold recommendations based on in-depth research. This consensus ...and more »
05/20/16 10:13 AMAntares Pharma, Inc. (NASDAQ:ATRS) Hovering Around $0.8400 - Investor Newswire - Antares Pharma, Inc. (NASDAQ:ATRS) Hovering Around $0.8400Investor NewswireOn performing technical analysis of Antares Pharma, Inc. (NASDAQ:ATRS) stock, it is noted that the stock is $-0.0694 points away -7.5467% from its fifty-day MA of $0.9192. It is $-0.2148 or -20.1796% away $1.0646, the 200-day MA (Moving Average) of stock.Broker Roundup For Antares Pharma, Inc. (ATRS)Share Trading NewsAntares Pharma, Inc. (ATRS) Updated Price TargetsFTSE NewsAntares Pharma, Inc. (NASDAQ:ATRS) One-Year Price Target Estimate At $3.70Equities Focusall 4 news articles »
05/19/16 06:00 PMETF’s with exposure to Antares Pharma, Inc. : May 19, 2016 -
05/18/16 10:43 AMRevenue Update on Antares Pharma Inc(NASDAQ:ATRS) - Trade Calls - Revenue Update on Antares Pharma Inc(NASDAQ:ATRS)Trade CallsAntares Pharma Inc(NASDAQ:ATRS) announced the earnings results for Fiscal Year 2016 and Q1. The results came in during Pre-market on May 9, 2016. Company reported revenue of $12.32M. Analysts estimated a revenue of $11.07M. Earnings per share ...
05/17/16 01:00 PMAntares Pharma, Inc. :ATRS-US: Earnings Analysis: Q1, 2016 By the Numbers -
05/17/16 12:04 PMANTARES PHARMA, INC. Financials -
05/14/16 05:59 PMTwo Healthcare Stocks of Yesterday: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) , Antares Pharma, Inc. (NASDAQ ... - Is stories - Two Healthcare Stocks of Yesterday: Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) , Antares Pharma, Inc. (NASDAQ ...Is storiesIn most recently trading session on 5/13/2016, Antares Pharma, Inc. (NASDAQ:ATRS) climbed +2.48% while traded on 308.1 thousand shares versus it's an average volume of 891.2 thousand shares. The company recorded the last trade with the price of ...and more »
05/14/16 05:59 PMAntares Pharma, Inc. (NASDAQ:ATRS) Latest Impact Score At 80 - Stocks Daily - Antares Pharma, Inc. (NASDAQ:ATRS) Latest Impact Score At 80Stocks DailyAntares Pharma, Inc. (NASDAQ:ATRS) has a 0.135 daily sentiment score given by Alpha One after scanning articles on various online news platform. Alpha One performs algorithm based analysis to reach stock sentiment based on content published on ...Antares Pharma, Inc. (NASDAQ:ATRS) Is $-1.77 Off Its 52-Week HighInvestor NewswireCan Antares Pharma, Inc. (NASDAQ:ATRS)'s Touch $3.70 In Coming Year?Equities Focusall 3 news articles »
05/13/16 11:51 PMShort Interest Moves 16.5% Lower For ATRS - The most recent short interest data has been released for the 04/29/2016 settlement date, which shows a 1,852,957 share decrease in total short interest for Antares Pharma Inc. (ATRS), to 9,381,683, a decrease of 16.49% since 04/15/2016. Total short ...
05/12/16 06:49 PMCurrent Update on Price Fluctuations: Haemonetics Corporation (NYSE:HAE) , Antares Pharma, Inc. (NASDAQ:ATRS) - Street Updates - Current Update on Price Fluctuations: Haemonetics Corporation (NYSE:HAE) , Antares Pharma, Inc. (NASDAQ:ATRS)Street UpdatesOn 5/11/2016, Haemonetics Corporation (NYSE:HAE) ended trading session lower at $26.89 with -2.18%. The company traded a volume of 707.61 thousand shares as comparison to average volume of 358.9 thousand shares. During the 52 –week period, ...Altiris Inc (NASDAQ:ATRS) Sentiment Increased in Q4 2015The Postall 2 news articles »
05/11/16 06:51 PMAntares Pharma Inc (ATRS) to Post FY2018 Earnings of $0.09 Per Share, Jefferies Group Forecasts - Washington News Wire - Washington News WireAntares Pharma Inc (ATRS) to Post FY2018 Earnings of $0.09 Per Share, Jefferies Group ForecastsWashington News WireAntares Pharma logo Antares Pharma Inc (NASDAQ:ATRS) – Equities researchers at Jefferies Group dropped their FY2018 EPS estimates for shares of Antares Pharma in a note issued to investors on Tuesday, Zacks Investment Research reports. Jefferies ...Antares Pharma Inc. (ATRS) Drops 6.69% on May 10Equities.comAnalysts Set $3.00 Price Target for Antares Pharma Inc (NASDAQ:ATRS)NewsWay 21Analyst Review: Antares Pharma, Inc. (ATRS)Risers & FallersWeb Breaking News -News Tribuneall 8 news articles »
About Antares Pharma

Antares Pharma logoAntares Pharma, Inc. (Antares) is a specialty pharmaceutical Company that focuses on developing and commercializing self-administered parenteral pharmaceutical products and technologies. The Company develops and manufactures for itself and with partners, pressure-assisted injectors, with and without needles, which allow patients to self-inject drugs. It has developed variations of the needle-free injector by adding a small shielded needle to a pre-filled, single-use disposable injector, called the Vibex pressure assisted auto injection system. This system is an alternative to the needle-free system for use with injectable drugs in unit dose containers and is suitable for branded and generic injectables. It has also developed a disposable multi-dose pen injector for use with standard cartridges.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Medical Instruments & Supplies
  • Sub-Industry: Health Care Supplies
  • Exchange: NASDAQ
  • Symbol: ATRS
  • CUSIP: 03664210
Key Metrics:
  • Previous Close: $1.01
  • 50 Day Moving Average: $0.9686
  • 200 Day Moving Average: $1.0025
  • P/E Ratio: N/A
  • P/E Growth: -0.0800
  • Market Cap: $147.68M
  • Current Quarter EPS Consensus Estimate: $-0.1600 EPS
Additional Links:
Antares Pharma (NASDAQ:ATRS) Chart for Saturday, June, 25, 2016


            As Featured by CNBC As Featured by The Wall Street Journal As Featured by MarketWatch As Featured by The Boston Globe As Featured by StockTwits As Featured by Seeking Alpha